Breaking the Dilemma in HER2-Positive Tumors: New Progress in Clinical Application of Tucatinib/Tucatinib and Analysis of Global Drug Accessibility

Introduction: New expansion in the HER2 targeting era

Since the introduction of anti-HER2 antibodies such as trastuzumab, significant progress has been made in the treatment of HER2-positive tumors, especiallybreast cancer. However, in many cases, the role of antibody drugs in penetrating the blood-brain barrier and in the context of tumor resistance is limited. /Tucatinib (Tucatinib, also known as tucatinib, TUKYSA) is an oral small molecule HER2 tyrosine kinase inhibitor, which is designed to improve the ability to inhibit the HER2 signaling pathway and also has certain central nervous system effects. With the publication of multiple clinical studies in recent years, tucatinib is gradually demonstrating its potential in breast cancer, colorectal cancer, and even a wider range of HER2-driven tumors.

xa0

1. Latest progress of tucatinib in HER2+ breast cancer

1.1 HER2CLIMB and subsequent results solidify its position

Tucatinib initially gained widespread attention based on the HER2CLIMB study. The study allowed HER2+ breast cancer patients with brain metastases to be enrolled. The results showed that the tucatinib combined with trastuzumab and capecitabine group had significant benefits in terms of progression-free survival (PFS) and overall survival (OS) compared with the control group. In this study, in the subgroup of patients with brain metastases, the tucatinib combination prolonged median OS by 9.1 months and median CNS-PFS was also significantly better than control.

In recent months, new combination research results have been released. For example, theHER2CLIMB-02 study explores adding tucatinib to T-DM1 (ado-trastuzumab emtansine) treatment. The latest report showed that adding tucatinib further reduced the risk of disease progression or death (median PFS increased from 7.4 months to 9.5 months) compared with T-DM1 alone. Although this result is not a revolutionary leap in improving efficacy, it shows that the value of tucatinib is being continuously explored on the basis of late-line or existing anti-HER2 antibody drugs.

Overall, the status of tucatinib in HER2+ breast cancer has gradually stabilized, and it continues to be explored in combinations, late-line or special subtypes, and its scope of action is evolving into a more strategic choice.

xa0

1.2 A new perspective on treatment options for patients with “migration + brain metastasis”

In clinical practice, brain metastasis is one of the common progression sites of HER2+ breast cancer. Traditional antibody drugs (such as trastuzumab, pertuzumab, and T-DM1) are not ideal for controlling the disease in the brain due to their large molecules and limited ability to penetrate the blood-brain barrier. As a small molecule HER2 inhibitor, tucatinib itself has certain central nervous system penetration (although not as significant as some small molecule EGFR inhibitors) and is considered to have certain potential for brain metastasis control.

Some studies have pointed out that in the subgroup of patients with brain metastases, the tucatinib combination can significantly extend the median OS (eg, 21.6 months vs. 12.5 months) and the median CNS-PFS (9.9 months vs. 4.2 months). Based on these data, guidelines such as European ESMO and American ASCO have considered tucatinib + capecitabine + trastuzumab as one of the alternatives in the presence of brain metastases, delaying the timing of local treatment (such as radiotherapy, surgery) in the context of multidisciplinary collaboration.

In recent years, some reports have also pointed out that when brain metastases are stable and the lesions in the body are well controlled, it may be feasible to use tucatinib as a maintenance or switching regimen. However, it should be pointed out that there is currently a lack of clear first-line forward-looking data to support this strategy.

xa0

2. Tucatinib’s “cross-border” attempt in HER2+ colorectal cancer

2.1 MOUNTAINEER study promotes accelerated FDA approval

In 2023, the FDA approved tucatinib plus trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (as an accelerated approval). The approval was based on the MOUNTAINEER study (NCT03043313), which enrolled 84 patients who were given tucatinib + trastuzumab in the setting of previous treatment failure with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.

In this study, the combination achieved high objective response rate (ORR) and stable disease control rate (disease control rate) of approximately 38%. The FDA’s accelerated approval highlights its unmet need in the treatment of “refractory HER2+ colorectal cancer.” Some commentators pointed out that this approval not only marks the first time tucatinib has entered the field of colorectal cancer, but also reflects the trend of expanding the concept of targeted therapy to more cancer types.

xa0

2.2 Exploration of first-line combination regimen: mFOLFOX6 + tucatinib + trastuzumab

Even more cutting-edge, an early-stage study is exploring the addition of tucatinib to standard chemotherapy for the first-line treatment of HER2+ colorectal cancer For example, studies are examining the safety and preliminary efficacy of mFOLFOX6 (fluoropyrimidine + oxaliplatin regimen) combined with tucatinib + trastuzumab. If this combination can show better efficacy subject to safety approval, it is expected to change the current treatment sequence for HER2+ colorectal cancer.

However, such attempts are still in the early stages, and comparative data on a sufficient scale have not yet been generated. Whether it can surpass standard chemotherapy + anti-EGFR/anti-VEGF regimen in first-line treatment in the future needs to be carefully observed.

xa0

2.3 Challenges and Strategies of HER2 Targeting in Colorectal Cancer

Even in HER2+ colorectal cancer, there are challenges for tucatinib to work. Studies have pointed out that pure HER2-targeting strategies (including dual-targeting antibodies or small molecule combinations) may cause early progression (primary resistance) in some patients. The mechanism is related to factors such as intra-tumor heterogeneity, activation of co-driven signaling pathways, low HER2 copy number, and RTK/MAPK pathway alternative pathway activation.

Therefore, in the future, the choice of more refined genomic screens (including HER2 copy number, coexisting mutations, ctDNA dynamic monitoring, etc.) may be the key to improving targeting success rates. In addition, strategies such as antibody-drug conjugates (ADCs), bispecific antibodies, small molecule + antibody combinations, and immunotherapy combinations are also regarded as future breakthroughs.

xa0

3. Domestic Accessibility and Global Access Challenges

3.1 Not yet listed in China and policy obstacles

As pointed out, the original drug of Tucatinib (Tucatinib) has not yet been approved for marketing in the Chinese market, so it cannot yet be included in the domestic medical insurance system. This is the result of multiple complex factors including registration approval, clinical trial data, domestic indication verification, and drug approval pathways.

xa0

3.2 International access and pricing pressure

Tucatinib has been approved for HER2+ breast cancer in many regions such as Europe, the United States, Japan, and the European Union. HER2+ breast cancer is still being considered or has been included in colorectal cancer indications in some countries. In its review of Tukysa, the European Medicines Agency (EMA) stipulates that the combination of tucatinib + capecitabine + trastuzumab can be used in patients with HER2+ locally advanced or metastatic breast cancer after failure of at least two anti-HER2 therapies. However, prices and reimbursement policies vary greatly across regions. The original drug (150mg × 84 tablets) is priced in the EU at more than 40,000 yuan equivalent to RMB.

xa0

3.3 Generic drugs / international cooperation / strategic path to enter the Chinese market

In countries where it is not yet available (such as China), generics or imported versions (authorized or "imported generics") may be the faster route to accessibility. Generic drugs of tucatinib are already on the market in some regions (for example, Laos ASEAN Pharmaceuticals). The generic drugs produced in 150 mg × 60 tablets are priced at more than 2,000 yuan.

xa0

IV.Conclusion

As a relatively new HER2 small molecule inhibitor Tucatinib’s entry into breast cancer, its “cross-border” attempts into colorectal cancer, and its role in patients with brain metastases make it a very bright candidate drug in the current field of HER2 targeted therapy.

xa0

References:

Tucatinib plus trastuzumab demonstrates safety, efficacy in HER2-mutated breast cancer. Pharmacy Times.

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive metastatic colorectal cancer (PubMed)

Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 & HER2CLIMB-05 (OncLive)

FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. U.S. FDA

Clinical Trials Using Tucatinib (Cancer.gov / NCI)